EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis

Vivek Jha, Sanjay Kumar Bhadada, Soham Mukherjee, Rimesh Pal, Chirag Kharbanda

Bone · 2026

DOI: 10.1016/j.bone.2026.118003 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Bone, 2026. Verfasst von Vivek Jha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India. Hauptthemen laut MEDLINE: Collagen Type I, Imidazoles, Diphosphonates, Body Mass Index. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate whether baseline bone turnover markers (BTMs), particularly plasma β-C-terminal telopeptide of type I collagen (β-CTX), and body mass index (BMI) predict the feasibility and short-term safety of deferring zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis. METHODS: In this prospective observational study, 50 treatment-naïve postmenopausal women with DXA-confirmed osteoporosis received intravenous zoledronic acid (5 mg). At the 12-month visit, β-CTX guided repeat dosing: women with β-CTX ≥300 pg/mL were redosed, whereas those with β-CTX 12 months). RESULTS: Twenty-five women underwent delayed redosing (median interval 18.5 months). Compared with standard dosing, the delayed group had lower baseline β-CTX (582 vs 866 pg/mL; p < 0.001) and lower BMI (23.4 ± 5.5 vs 25.7 ± 2.0 kg/m2; p = 0.008). On multivariable analysis, lower baseline β-CTX (adjusted OR per 100 pg/mL 0.48; 95% CI 0.31-0.73; p = 0.001) and lower BMI (adjusted OR per kg/m2 0.81; 95% CI 0.67-0.98; p = 0.031) independently predicted delayed redosing. BMD gains were comparable between groups and no new vertebral fractures occurred during 2-year follow-up. CONCLUSION: Lower baseline bone turnover and lower BMI were associated with delayed zoledronic acid redosing, supporting a biomarker-guided approach to individualized treatment intervals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Collagen Type IImidazolesDiphosphonatesBody Mass IndexPeptidesOsteoporosis, PostmenopausalBone Density Conservation AgentsHumansZoledronic AcidFemaleMiddle AgedIndiaAgedBiomarkersProspective StudiesPostmenopauseBone Density

Stichwörter der Autor:innen

Body mass indexBone turnover markersOsteoporosisPostmenopausal womenZoledronic acidβ-CTX

Substanzen

Zoledronic AcidCollagen Type IImidazolesDiphosphonatescollagen type I trimeric cross-linked peptidePeptidesBone Density Conservation AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India.
  • Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India. Electronic address: bhadadask@rediffmail.com.

Zitieren

APA

Jha, V., Bhadada, S. K., Mukherjee, S., Pal, R., & Kharbanda, C. (2026). Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis. Bone. https://doi.org/10.1016/j.bone.2026.118003

Vancouver

Jha V, Bhadada SK, Mukherjee S, Pal R, Kharbanda C. Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis. Bone. 2026. doi:10.1016/j.bone.2026.118003

BibTeX
@article{Jha2026,
  author = {Jha, Vivek and Bhadada, Sanjay Kumar and Mukherjee, Soham and Pal, Rimesh and Kharbanda, Chirag},
  title = {Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis},
  journal = {Bone},
  year = {2026},
  doi = {10.1016/j.bone.2026.118003}
}
Kostenlos starten →